{"id":"quetiapine-risperidone","_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=quetiapine, risperidone","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:12:00.095532+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:12:06.732567+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=quetiapine, risperidone","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:12:07.500017+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Dopamine D2 receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:12:08.064602+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3188993/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:12:07.971160+00:00"}},"_dailymed":null,"_scrapedAt":"2026-03-28T00:03:30.886Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:12:09.890553+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT05741502","phase":"PHASE4","title":"An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2023-08-16","conditions":"Treatment-resistant Schizophrenia","enrollment":5},{"nctId":"NCT02926859","phase":"PHASE2","title":"Enhancing Recovery in Early Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2017-04-08","conditions":"Schizophrenia","enrollment":180},{"nctId":"NCT06581302","phase":"NA","title":"Magnetic Seizure Therapy for Psychotic Disorders","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-09-01","conditions":"Psychotic Disorders","enrollment":50},{"nctId":"NCT01246765","phase":"","title":"National Pregnancy Registry for Psychiatric Medications","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2008-11","conditions":"Pregnant Women, Psychotropic Drugs","enrollment":5000},{"nctId":"NCT06049953","phase":"","title":"Maternal And Infant Antipsychotic Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-09-29","conditions":"Antipsychotics, Pregnancy","enrollment":200},{"nctId":"NCT07152184","phase":"PHASE2","title":"Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-01-01","conditions":"Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology, Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":288},{"nctId":"NCT04002700","phase":"","title":"A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-05-06","conditions":"Stroke","enrollment":1234412},{"nctId":"NCT07024303","phase":"EARLY_PHASE1","title":"Measurement of Treatment Effects","status":"NOT_YET_RECRUITING","sponsor":"Matthew J O'Brien, PhD, BCBA-D","startDate":"2025-06-15","conditions":"Challenging Behavior, Autism Spectrum Disorder","enrollment":20},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT03666715","phase":"","title":"A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal","status":"COMPLETED","sponsor":"Janssen-Cilag Farmaceutica Ltda.","startDate":"2018-08-07","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT02958800","phase":"NA","title":"Deprescribing Antipsychotics in Long-Term Care","status":"COMPLETED","sponsor":"McMaster University","startDate":"2016-12","conditions":"Dementia, Behavior","enrollment":6},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT03818256","phase":"PHASE2","title":"A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2019-12-04","conditions":"Antipsychotic-induced Weight Gain (AIWG)","enrollment":71},{"nctId":"NCT06482554","phase":"PHASE3","title":"Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.","status":"RECRUITING","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"2024-06","conditions":"Apathy, Schizophrenia, Schizophrenia; Psychosis","enrollment":80},{"nctId":"NCT05402111","phase":"PHASE1","title":"A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-06-13","conditions":"Schizophrenia","enrollment":31},{"nctId":"NCT05542264","phase":"PHASE1","title":"A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-11-15","conditions":"Schizophrenia","enrollment":19},{"nctId":"NCT02366897","phase":"NA","title":"Extrapyramidal Side-Effects in Antipsychotic Drug Therapeutics","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2017-02-21","conditions":"Drug-induced Extrapyramidal Side Effects","enrollment":21},{"nctId":"NCT04524403","phase":"PHASE2","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2020-09-09","conditions":"Antipsychotic-induced Weight Gain (AIWG)","enrollment":150},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT06200584","phase":"NA","title":"Synergistic Effect of Vitamin E & D in Reducing Risk of Effects Associated With Atypical Anti-psychotics","status":"COMPLETED","sponsor":"Dr Rabia Arshad","startDate":"2021-01-01","conditions":"Antipsychotics and Neuroleptics Toxicity","enrollment":140},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":"Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy","enrollment":180},{"nctId":"NCT06040944","phase":"","title":"Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2022-09-01","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders, Periodontal Diseases","enrollment":64},{"nctId":"NCT04312503","phase":"","title":"Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia\"","status":"COMPLETED","sponsor":"Aziende Chimiche Riunite Angelini Francesco S.p.A","startDate":"2020-07-13","conditions":"Schizophrenia","enrollment":95},{"nctId":"NCT05833399","phase":"","title":"Correlation of Genetic Variations With Clinical Response in Substance Use Disorder","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-11-28","conditions":"Substance Use Disorders, Substance Dependence","enrollment":200},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT01052103","phase":"PHASE2","title":"A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2010-01","conditions":"Schizophrenia","enrollment":167},{"nctId":"NCT00448630","phase":"","title":"An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-10-23","conditions":"Schizophrenia, Metabolic Syndrome X","enrollment":328},{"nctId":"NCT01498770","phase":"","title":"An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-04-01","conditions":"Bipolar Disorder","enrollment":42},{"nctId":"NCT02213887","phase":"PHASE4","title":"Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2014-09","conditions":"Psychotic Disorders, Gastroesophageal Reflux","enrollment":""},{"nctId":"NCT03019887","phase":"NA","title":"Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction","status":"COMPLETED","sponsor":"Juntendo University","startDate":"2011-04","conditions":"Schizophrenia Relapse","enrollment":139},{"nctId":"NCT03565068","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-20","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT03319953","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2017-12-21","conditions":"Stable Schizophrenia","enrollment":23},{"nctId":"NCT00159770","phase":"PHASE3","title":"Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2001-11","conditions":"Schizophrenia, Schizoaffective Disorder, Psychotic Disorders","enrollment":290},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":"Schizophrenia","enrollment":174},{"nctId":"NCT04446234","phase":"PHASE4","title":"Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2021-05","conditions":"Schizophrenia","enrollment":350},{"nctId":"NCT03568500","phase":"PHASE4","title":"A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-05-21","conditions":"Schizophrenia, Schizoaffective Disorder, First Episode Psychosis","enrollment":44},{"nctId":"NCT02181803","phase":"PHASE1","title":"MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-05","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT03007303","phase":"","title":"The Relevance Between the microRNA-30e in Plasma and the Prognosis of Schizophrenia Patients","status":"UNKNOWN","sponsor":"Dalian Seventh People's Hospital","startDate":"2016-06","conditions":"Schizophrenia, Micrognathia","enrollment":30},{"nctId":"NCT00515723","phase":"NA","title":"Glucose and Lipid Metabolism on Antipsychotic Medication","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2001-09","conditions":"Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus","enrollment":96},{"nctId":"NCT00161018","phase":"PHASE3","title":"New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2003-11","conditions":"Schizophrenia","enrollment":150},{"nctId":"NCT02600741","phase":"","title":"Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-24","conditions":"Schizophrenia","enrollment":296},{"nctId":"NCT01231074","phase":"PHASE1","title":"Reducing Antipsychotic-Induced Weight Gain in Children With Metformin","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2010-02","conditions":"Obesity, Weight Gain, Psychotropic Induced Weight Gain","enrollment":96},{"nctId":"NCT02307396","phase":"PHASE4","title":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-02-01","conditions":"Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders","enrollment":21},{"nctId":"NCT02562287","phase":"PHASE4","title":"Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2015-10","conditions":"Bipolar Disorder","enrollment":54},{"nctId":"NCT02529163","phase":"NA","title":"Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms","status":"UNKNOWN","sponsor":"Centre for Addiction and Mental Health","startDate":"2015-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":24},{"nctId":"NCT00330863","phase":"PHASE4","title":"Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2006-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":357},{"nctId":"NCT00509067","phase":"PHASE2","title":"Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2007-11","conditions":"Schizophrenia","enrollment":43},{"nctId":"NCT02051387","phase":"PHASE1","title":"Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study","status":"COMPLETED","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2013-01","conditions":"Schizophrenia","enrollment":74},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT00667745","phase":"PHASE4","title":"Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2008-04","conditions":"Bipolar Disorder","enrollment":283},{"nctId":"NCT00806234","phase":"PHASE4","title":"Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-01","conditions":"Psychotic Disorders","enrollment":127},{"nctId":"NCT02462473","phase":"PHASE2","title":"A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":9},{"nctId":"NCT02423096","phase":"","title":"Neuroendocrine and Metabolite Substrates in Schizophrenia","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2013-12","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT00423878","phase":"PHASE4","title":"Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2007-01","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":215},{"nctId":"NCT02192723","phase":"NA","title":"A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia","status":"COMPLETED","sponsor":"Beijing HuiLongGuan Hospital","startDate":"2012-06","conditions":"Schizophrenia","enrollment":550},{"nctId":"NCT01739127","phase":"","title":"Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2012-11","conditions":"Psychotic Disorders, Bipolar Disorder, Metabolic Syndrome X","enrollment":83},{"nctId":"NCT00439634","phase":"PHASE2","title":"Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2007-02","conditions":"Schizophrenia","enrollment":873},{"nctId":"NCT00044655","phase":"PHASE4","title":"Switching Medication to Treat Schizophrenia","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2001-07","conditions":"Schizophrenia","enrollment":219},{"nctId":"NCT00177164","phase":"PHASE3","title":"Risperdal Consta for Bipolar Disorder","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2003-11","conditions":"Bipolar I Disorder","enrollment":50},{"nctId":"NCT01844700","phase":"PHASE4","title":"1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain","status":"TERMINATED","sponsor":"Northwell Health","startDate":"2013-07","conditions":"High Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime Exposure","enrollment":14},{"nctId":"NCT02650102","phase":"PHASE1, PHASE2","title":"The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment","status":"UNKNOWN","sponsor":"Shanxi Medical University","startDate":"2013-01","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT00272025","phase":"PHASE1","title":"Treatment Resistant Bipolar Depression","status":"TERMINATED","sponsor":"Queen's University","startDate":"2006-10","conditions":"Bipolar Depression","enrollment":1},{"nctId":"NCT02087579","phase":"PHASE1","title":"Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02","conditions":"Psychotic Disorders, Schizophrenia, Bipolar Disorder","enrollment":305},{"nctId":"NCT02582736","phase":"","title":"Antipsychotics and Risk of Hyperglycemic Emergencies","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-04","conditions":"Psychotic Disorders, Schizophrenia, Schizoaffective Disorder","enrollment":725489},{"nctId":"NCT01305707","phase":"PHASE4","title":"Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression","status":"TERMINATED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2009-07","conditions":"Depression","enrollment":104},{"nctId":"NCT00015548","phase":"NA","title":"CATIE-Alzheimer's Disease Trial","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2001-03","conditions":"Alzheimer's Disease","enrollment":450},{"nctId":"NCT00014001","phase":"PHASE4","title":"CATIE- Schizophrenia Trial","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2000-12","conditions":"Schizophrenia","enrollment":1600},{"nctId":"NCT02282085","phase":"PHASE4","title":"Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia","status":"UNKNOWN","sponsor":"Matt Byerly","startDate":"2014-12","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT01157351","phase":"PHASE4","title":"15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2010-05","conditions":"Schizophrenia","enrollment":450},{"nctId":"NCT01786369","phase":"","title":"Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics.","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2013-02","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar Disorder","enrollment":106},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":"Psychosis Nos/Other","enrollment":104},{"nctId":"NCT00237861","phase":"PHASE4","title":"Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia","status":"COMPLETED","sponsor":"Yale University","startDate":"","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT01323205","phase":"PHASE2","title":"Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-05","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT02137616","phase":"NA","title":"Antipsychotic to Treat Psychosis Syndrome","status":"UNKNOWN","sponsor":"Central South University","startDate":"2012-06","conditions":"Psychotic Disorders","enrollment":300},{"nctId":"NCT01894984","phase":"","title":"An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia","status":"TERMINATED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2007-01","conditions":"Schizophrenia","enrollment":640},{"nctId":"NCT00216476","phase":"PHASE3","title":"A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2004-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":753},{"nctId":"NCT00048802","phase":"PHASE4","title":"Treatment and Outcome of Early Onset Bipolar Disorder","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2002-08","conditions":"Bipolar Disorder","enrollment":40},{"nctId":"NCT02040883","phase":"PHASE4","title":"Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia","status":"UNKNOWN","sponsor":"Qingyun Yin","startDate":"2014-02","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT00312598","phase":"","title":"Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2005-08","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":30},{"nctId":"NCT00508157","phase":"PHASE4","title":"A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2007-11","conditions":"Metabolic Syndrome, Schizophrenia","enrollment":125},{"nctId":"NCT00246259","phase":"PHASE4","title":"A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis","status":"COMPLETED","sponsor":"Janssen-Ortho Inc., Canada","startDate":"2004-10","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":77},{"nctId":"NCT00845988","phase":"PHASE4","title":"Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2008-12","conditions":"Bipolar Disorders, Metabolic Complication","enrollment":28},{"nctId":"NCT00857818","phase":"PHASE3","title":"Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-04","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder","enrollment":64},{"nctId":"NCT00208819","phase":"PHASE4","title":"A Comparison of Two Standard Therapies in the Management of Dementia With Agitation","status":"COMPLETED","sponsor":"Emory University","startDate":"2003-09","conditions":"Senile Dementia, Alzheimer Type, Dementia, Alzheimer Type, Alzheimer Disease","enrollment":50},{"nctId":"NCT00237913","phase":"PHASE3","title":"Schizophrenia Trial of Aripiprazole","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-07","conditions":"Schizophrenia","enrollment":700},{"nctId":"NCT00325689","phase":"PHASE4","title":"Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-07","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":323},{"nctId":"NCT01193166","phase":"PHASE4","title":"Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital","status":"WITHDRAWN","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2010-08","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT00182013","phase":"PHASE4","title":"Open-Label Comparative Study of Risperidone Versus Olanzapine Versus Quetiapine for Mania in Children and Adolescents With Bipolar I and Bipolar II Disorder","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2001-06","conditions":"Bipolar Spectrum Disorder","enrollment":106},{"nctId":"NCT00255879","phase":"PHASE1","title":"Movement Disorders Caused by Antipsychotic Drugs in Older Patients","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"1999-01","conditions":"Dyskinesia, Drug-Induced","enrollment":250},{"nctId":"NCT01607762","phase":"PHASE1","title":"A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-02","conditions":"Healthy","enrollment":31},{"nctId":"NCT01129674","phase":"PHASE2, PHASE3","title":"A Long-Term, Open-Label, Study on Schizophrenia","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2010-06","conditions":"Schizophrenia","enrollment":1210},{"nctId":"NCT00206102","phase":"PHASE4","title":"A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-09","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":1098},{"nctId":"NCT00034905","phase":"PHASE4","title":"A Comparison of Seroquel vs. Risperidone in Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2001-07","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT00034892","phase":"PHASE3","title":"CAFE Comparison of Atypicals in First Episode of Psychosis","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-03","conditions":"Schizophrenia, Psychotic Disorders, Mental Health","enrollment":""},{"nctId":"NCT00600756","phase":"PHASE3","title":"Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Schizophrenic Disorders","enrollment":798},{"nctId":"NCT00488891","phase":"","title":"The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia","status":"TERMINATED","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2007-04","conditions":"Schizophrenia","enrollment":43},{"nctId":"NCT00833300","phase":"NA","title":"Haloperidol vs Olanzapine for the Management of ICU Delirium","status":"TERMINATED","sponsor":"Richard Hall","startDate":"2008-06","conditions":"Delirium, Agitation","enrollment":200},{"nctId":"NCT00640562","phase":"PHASE3","title":"Quetiapine Extended Release Depression Symptoms","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-02","conditions":"Schizophrenia, Depression","enrollment":216},{"nctId":"NCT01272765","phase":"PHASE2","title":"Anti-psychotic Medication (Stable Dose) Weight Loss Study","status":"WITHDRAWN","sponsor":"Avera McKennan Hospital & University Health Center","startDate":"2012-03","conditions":"Obesity","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL3188993"},"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Seroquel","Risperdal"],"phase":"marketed","status":"active","brandName":"quetiapine, risperidone","genericName":"quetiapine, risperidone","companyName":"University of Texas Southwestern Medical Center","companyId":"university-of-texas-southwestern-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:12:09.890553+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}